{"disease":{"id":"inflammatory-breast-cancer","name":"inflammatory breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02682693","title":"Denosumab as an add-on Neoadjuvant Treatment (GeparX)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":780,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":false},{"nct_id":"NCT05415215","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06131632","title":"Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03012100","title":"Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT00344071","title":"Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06954324","title":"Investigation of the Effect of Erector Spinae Plane Block on Systemic Immuno-Inflammatory Index","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Namik Kemal University","has_results":false},{"nct_id":"NCT01417286","title":"Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT01525966","title":"Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":67,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05795101","title":"TRUDI: TDXD+Durva in HER2+/Low IBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Filipa Lynce, MD","has_results":false},{"nct_id":"NCT03515798","title":"Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT04636710","title":"Refining Local-Regional Therapy for IBC","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05383196","title":"Onvansertib + Paclitaxel In TNBC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Antonio Giordano, MD","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT02971748","title":"Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03101748","title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00986609","title":"MUC1 Vaccine for Triple-negative Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Joseph Baar, MD, PhD","has_results":false},{"nct_id":"NCT03184558","title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"BerGenBio ASA","has_results":true},{"nct_id":"NCT05727813","title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT02658812","title":"Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03872388","title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02892734","title":"Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT05177796","title":"Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05093387","title":"SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06057636","title":"Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"The University of Tennessee, Knoxville","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}